pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
AMGEN · news · pharmadog
← back to AMGEN
News mentioning AMGEN
111
stories
19h
Scribe’s early-stage IPO standout defies biotech’s derisking trend
biospace
1d
Why pediatric rare oncology outperforms in a volatile biotech market
biospace
1d
Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy
fiercebiotech
1d
Amgen cans its TScan partnership; Amylyx reveals $350M offering
endpoints
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
2d
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
2d
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
biospace
4d
Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
fiercebiotech
4d
Baylor Genetics hit by cybersecurity attack targeting patient, staff information
fiercebiotech
6d
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
biopharma dive
6d
Pressure piles on Amgen after EU pulls Tavneos, flags 'serious breaches' in pivotal study
biospace
7d
'Incorrect and misleading' data prompted decision to pull Tavneos in Europe
endpoints
8d
July's biopharma layoffs affect 466 employees, a 94% year-over-year drop
biospace
8d
Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
fiercebiotech
8d
7 companies hiring in North Carolina now
biospace
9d
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
biospace
9d
Amgen lays groundwork for new R&D center in Hyderabad
fiercebiotech
11d
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
13d
Latigo IPO raises nearly $350M for pain drug development
biopharma dive
15d
The top 12 companies hiring in biopharma now
biospace
15d
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
15d
STAT+: Moderna launches early trial of Ebola mRNA vaccine
stat
15d
Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
biospace
16d
Amgen culls early-stage obesity candidate, makes pipeline updates
endpoints
16d
Amgen drops early-stage obesity drug, upping pressure on MariTide
fiercebiotech
17d
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
fiercebiotech
17d
STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more
stat
17d
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
17d
Amgen hit with cybersecurity breach, patient data affected
biospace
17d
Amgen says hackers stole patient data in cloud breach
endpoints
← prev
page 1 of 4
next →
